알림

Sionna Therapeutics Inc. (SION)

NasdaqGM: SION · 실시간 가격 · USD

6.00

+0.06 (1.01%)

종가 기준: Aug 18, 2026, 3:59 PM

1.01% (1D)

매수호가	35.98
시가총액	272.71M
매출 (ttm)	n/a
순이익 (ttm)	-97.38M
베타	n/a
EPS (ttm)	-2.15
P/E (ttm)	n/a
선행 P/E	-2.39
P/B (ttm)	1.03
P/S (ttm)	n/a
Earnings Date	Nov 5, 2026

매도호가	64.74
거래량	873,241
평균 거래량 (20일)	1,677,583
시가	6.09
전일 종가	5.94
일중 범위	5.88 - 6.28
52주 범위	4.01 - 54.97
애널리스트	Hold
목표주가	5.5 (-8.33%)
배당	n/a
배당락일	n/a

SION 소개

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector th...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Feb 7, 2025

직원 수 59

상장 거래소 NasdaqGM

티커 SION

웹사이트 https://www.sionnatx.com

전체 기업 정보

재무 실적

2025년 Sionna Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -75.27M로, 22.01% 증가했습니다.

재무제표

애널리스트 전망

애널리스트 6명의 투자의견을 종합하면 SION 주식의 평균 등급은 "Hold"입니다. 12개월 목표주가는 5.5로, 최근 주가 대비 8.33% 하락 여력입니다.

주가 전망

어닝 서프라이즈

Sionna Therapeutics가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.66 예상치 하회 -0.01, 및 -60.98% 전년 대비 감소.

다음 실적 발표

Sionna Therapeutics Inc.의 실적 발표 예정일은 Nov 5, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

6일 전 · Simply Wall St.

Sionna Therapeutics (SION) Resets After Trial Miss, Is The Discount Now Too Deep?

Sionna Therapeutics (SION) is back in focus after reporting topline results for its cystic fibrosis programs, including a Phase 2a proof of concept miss for SION-719 and supportive Phase 1 data for SI...

6일 전 · Simply Wall St.

Sionna Therapeutics (SION) Is Down 86.8% After Halting SION-719 And Refocusing Its CF Pipeline – Has The Bull Case Changed?

Sionna Therapeutics recently reported that its lead cystic fibrosis candidate SION-719 failed to meet the key activity endpoint in a Phase 2a proof-of-concept trial as an add-on to Trikafta, prompting...

6일 전 · MT Newswires

Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says

Vertex Pharmaceuticals (VRTX) has multiple potential catalysts coming from its portfolio that provid

1주 전 · Simply Wall St.

Sionna Therapeutics (SION) Stock Still Looks Cheap After The 90% Fall

Sionna Therapeutics stock has fallen sharply in recent sessions, yet the valuation checks suggest it is not a clear bargain even after the sell off. The share price reset sits alongside a low overall ...

1주 전 · Insider Monkey

One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses

Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc. (NASDAQ:SION) shares fell more than 90% following a key trial fail...

2 페이지 중 1

Sionna Therapeutics Inc. (SION)